Cardiac Rehabilitation for Young People

Heart Failure Clinical Trial

— CardioActive  

Official title:

Cardiac Rehabilitation for Young People: A Single-Blind Randomised Acceptability and Feasibility Study of an Integrated Physical and Mental Health Approach

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05968521
• Other study ID #: X638s
• Status: Recruiting
• Phase: N/A
• Start date: March 4, 2024
• Est. completion date: November 30, 2024

Study information

• Verified date: March 2024
• Source: Greater Manchester Mental Health NHS Foundation Trust
• Contact: Lora Capobianco, PhD
• Phone: 01610046664
• Email: lora.capobianco[@]gmmh.nhs.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Heart problems are amongst the most common physical illnesses in children and young people (CYP). They can be present from birth or develop as CYP get older and are linked to increased physical and psychological difficulties overprotection from caregivers and healthcare providers and reduced quality of life. While adults are offered exercise classes and lifestyle advice after a heart problem, CYP with heart problems are not. Improving health behaviours in people with heart problems is vital, improves quality of life and reduces additional illnesses (i.e obesity, diabetes). Approximately 1 in 3 CYP with heart problems have anxiety and/or depression so it is also important to support their mental health. One way to do this is to develop and test the acceptability and feasibility of a trial of cardiac rehabilitation (CR) consisting of exercise with mental health support for CYP. The aim is to develop and test the feasibility and acceptability of a trial of a cardiac rehabilitation programme for CYP.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: November 30, 2024
• Est. primary completion date: August 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 11 Years to 16 Years

Eligibility

All participants meeting the following inclusion criteria and aged between 11-16 years old will be eligible:

Inclusion Criteria:

1. Fluent in English

2. Consent to participate

3. Diagnosed with at least one of the following:

• Congenital heart disease (all subtypes)
• Cardiomyopathy
• Cardiac arrhythmia
• Heart failure
• Post-cerebrovascular event
• Post-heart valve repair/replacement

Exclusion Criteria:

1. Significant risk or safeguarding concerns (i.e., suicidal ideation)

2. Head injury/organic impairment

3. Significant social and/or communication difficulties Those with a formal diagnosis or under assessment for any above exclusion criteria will be excluded.

Related Conditions & MeSH terms

• Arrhythmias, Cardiac
• Cardiac Arrythmias
• Cardiomyopathies
• Congenital Heart Disease
• Heart Defects, Congenital
• Heart Diseases
• Heart Failure
• Heart Valve Diseases

Intervention

Behavioral:
• Cardiac Rehabilitation (CR): Experimental
CR will consist of six sessions lasting 90 minutes of a structured exercise programme, educational and lifestyle modules, and a psychological component. Sessions include group discussions, experiential learning and homework tasks that participants are asked to complete between sessions. Participants in this treatment arm will also receive routine clinical outpatient management alongside CR.
• Treatment as usual: Control
Treatment as usual will include routine clinical outpatient management.

Locations

Country	Name	City	State
United Kingdom	Manchester University NHS Foundation Trust	Manchester

Sponsors (4)

Lead Sponsor	Collaborator
Greater Manchester Mental Health NHS Foundation Trust	National Institute for Health Research, United Kingdom, University of Manchester, University of York

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recruitment Rate (Feasibility Outcome)	Feasibility will be assessed using recruitment rate (i.e., number of patients consented and randomized, number of patients declined the study).	Date of Baseline Assessment to end of follow-up (24 week follow up)
Primary	Retention Rate (Feasibility Outcome)	Feasibility will be assessed using retention rates (i.e., number of patients withdrawn from the study, lost to follow up)	Date of Baseline Assessment to end of follow-up (24 week follow up)
Primary	Intervention Attendance (Feasibility Outcome)	Feasibility will be assessed using participant attendance at intervention (i.e., number of sessions attended at the intervention).	Date of Baseline Assessment to end of follow-up (24 week follow up)
Primary	Acceptability of the Intervention	Acceptability of the intervention will be assessed in qualitative semi-structured interviews with children and young people, caregivers, and healthcare professionals, which will assess individuals views on the intervention, targets for improvement, and perceived acceptability of the components of the cardiac rehabilitation programme.	Date of Baseline Assessment to end of follow-up (24 week follow up)
Secondary	Strength and Difficulties Questionnaire (SDQ)	The SDQ measures psychological wellbeing across five subscales: emotion, hyperactivity, conduct, peer relations and pro-social behaviour. The SDQ can be completed by CYP and caregivers.; Score for the subscales range from 0-10, with a total difficulties score (0-40) generated by summing together the scores from all subscales except the pro-social subscale. Higher scores on the pro-social scale reflect strengths whereas higher scores across other subscales reflect difficulties.	Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Secondary	Paediatric Quality of Life (PedsQol)	The PedsQol is a 23 item measures of health related quality of life, and includes four subscales: physical, emotional, social and school functioning. The questionnaire is commonly used in paediatric cardiology. The PedsQol will be completed by CYP.; The items are scores from 0 (Never) to 4 (Almost always). Total scores range from 0-100, with higher scores indicating better quality of life.	Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Secondary	Six minute walk test (6MWT)	The 6MWT is used to assess aerobic capacity and endurance. Performance on the 6MWT has been predictive of morbidity and mortality whereby poorer performance is associated with increased mortality.	Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Secondary	Incremental Shuttle Walk Test (ISWT)	The ISWT is used to measure maximal exercise capacity. The ISWT is a 12-level test (1 min at each level), whereby participants walk up and down a 10, course with increasing accelearion of 0.17 m/s up to a maximum speed of 2.37 m/s. Walking speed is dicated by an audio signal. The test ends when the subject has a heart rate greater than 85% of their predicted maximum, is limited by dyspnoea or when the participant is unable to maintain the required speed and doe snot complete a shuttle for second consecutive time. The distance covered from the number of shuttles will be calculated.	Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Secondary	Physical Activity Monitoring	Participants will wear an accelerometer (Actigraph) for 5 days to monitor physical activity levels at each assessment.	Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Secondary	Metacognition Questionnaire-Adolescent (MCQ-A)	The MCQ-A assesses metacognitive beliefs (beliefs about thinking) across five subscales (uncontrollability of worry, need to control thoughts, cognitive self-consciousness, positive beliefs about worry, and cognitive confidence). The measure contains 30 items and is scored on a likert scale from 1 (do not agree) to 4 (agree very much). Total scores range from 30-120 and 6 to 30 for each subscale. Greater scores indicate greater maladaptive metacognitive beliefs.; The measure and will be completed by CYP.	Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Secondary	Child Health Utility-9D (CHU-9D)	The CHU-9D measures quality of life using nine dimensions (worried, sad, pain, tired, annoyed, schoolwork/homework, sleep, daily routine, and ability to join in activities). Each item has 5 levels ranging from no problems to inability to do the item. Responses will be used to generate utility values in the health economic evaluation. The CHU-9D will be completed by CYP.	Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Secondary	Health and Social Care Service-Use Questionnaire	The questionnaire will include questions about whether the child has used any primary, secondary, or community-based health and social care and how often they used the service in the last 16 weeks (baseline study visit) or since the last assessment (follow-up study visits). The questionnaire will be developed from existing child relevant service use questionnaires held by the co-applicants and through discussion with the patient and public involvement representative, parent advisory group and clinical members of the study team. This will be completed by parents/primary caregivers. The responses given and the patient feedback will be used to further refine the health-resource use questionnaire ahead of the definitive study.	Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Secondary	Demographics Questionnaire	The demographics questionnaire will collect variables such as participants age, sex, weight, height, BMI, type of heart problem, comorbid mental and physical illnesses, ethnicity, medication, socioeconomic status, parental occupational status. This will be completed by the parents/primary caregivers.	Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)